Yarbrough Capital LLC Acquires New Shares in DexCom, Inc. (NASDAQ:DXCM)

Yarbrough Capital LLC acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 2,787 shares of the medical device company’s stock, valued at approximately $217,000.

Other hedge funds have also bought and sold shares of the company. B. Riley Wealth Advisors Inc. grew its stake in shares of DexCom by 4.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock worth $445,000 after acquiring an additional 162 shares during the period. Crossmark Global Holdings Inc. raised its stake in DexCom by 1.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after buying an additional 182 shares during the last quarter. Riverview Trust Co raised its stake in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares during the last quarter. Koa Wealth Management LLC lifted its holdings in shares of DexCom by 7.7% during the 3rd quarter. Koa Wealth Management LLC now owns 3,770 shares of the medical device company’s stock valued at $253,000 after buying an additional 270 shares during the period. Finally, Freedom Investment Management Inc. boosted its stake in shares of DexCom by 10.2% in the 3rd quarter. Freedom Investment Management Inc. now owns 3,035 shares of the medical device company’s stock worth $203,000 after buying an additional 281 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.30% of the company’s stock.

DexCom Trading Up 5.5 %

DXCM opened at $84.84 on Friday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock has a market cap of $33.14 billion, a price-to-earnings ratio of 50.80, a P/E/G ratio of 2.00 and a beta of 1.12. The stock’s 50 day moving average price is $77.89 and its 200-day moving average price is $78.41.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on DXCM. Canaccord Genuity Group upped their target price on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a report on Monday, December 9th. JPMorgan Chase & Co. lifted their target price on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Leerink Partners lowered their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, Sanford C. Bernstein raised their target price on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.29.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.